Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment

@article{Yan2020AdvantagesOT,
  title={Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment},
  author={Victoria C. Yan and Florian L. Muller},
  journal={ACS Medicinal Chemistry Letters},
  year={2020},
  volume={11},
  pages={1361 - 1366}
}
While remdesivir has garnered much hope for its moderate anti-Covid-19 effects, its parent nucleoside, GS-441524, has been overlooked. Pharmacokinetic analysis of remdesivir evidences premature serum hydrolysis to GS-441524; GS-441524 is the predominant metabolite reaching the lungs. With its synthetic simplicity and in vivo efficacy in the veterinary setting, we contend that GS-441524 is superior to remdesivir for Covid-19 treatment. 
Pharmacokinetics of Orally Administered GS-441524 in Dogs
TLDR
The oral bioavailability of GS-441524 in beagle dogs is assessed and it is shown that plasma concentrations ∼24-fold higher than the EC50 against SARS-CoV-2 are easily and safely sustained.
Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment
  • Jiashu Xie, Zhengqiang Wang
  • Chemistry, Medicine
    Acta Pharmaceutica Sinica B
  • 2021
TLDR
GS-441524 produced adequate drug exposure in the mice plasma and lung, and was effectively converted to the active triphosphate, suggesting that it could be a promising oral antiviral drug for treating COVID-19.
Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside
TLDR
Overall, remdesivir exhibited greater potency and superior intracellular metabolism than GS-441524 except in Vero E6 and Vero CCL-81 cells.
Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mice Models
TLDR
The parent nucleotide of remdesivir, GS-441524, potently inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Vero E6 and other cells and supported that GS- 441524 as a promising and inexpensive drug candidate in the treatment of COVID-19 and future emerging CoVs diseases.
Remdesivir: Quo vadis?
TLDR
Its clinical efficacy has been evaluated, but needs to be optimized with regard to timing, dosage and duration of treatment, and route of administration, and safety, toxicity and pharmacokinetics need to be further addressed.
Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid Prodrugs
TLDR
New oral lipid prodrugs of Remdesivir nucleoside had submicromolar anti-SARS-CoV-2 activity in a variety of cell types including Vero E6, Calu-3, Caco-2, human pluripotent stem cell (PSC)-derived lung cells and Huh7.5 cells.
Rethinking Remdesivir: Synthesis of Lipid Prodrugs that Substantially Enhance Anti-Coronavirus Activity.
TLDR
Two of the three new lipid prodrugs of RVn had anti-SARS-CoV-2 activity 9 to 24 times greater than that of RDV in Vero E6 cells and likely improved oral bioavailability and simpler metabolic activation.
Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models
TLDR
Challenge studies in both an AAV-hACE2 mouse model of SARS-CoV-2 and in mice infected with murine hepatitis virus showed that GS-441524 was highly efficacious in reducing the viral titers in CoV-infected organs without notable toxicity.
Tissue level profile of SARS-CoV-2 antivirals in mice to predict their effects in COVID-19 multiorgan failure
TLDR
The mouse model was able to characterise the PK and tissue distribution of both model substances and is a suitable tool to investigate early drug candidates against SARS-CoV-2.
Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir’s Nephrotoxicity
TLDR
The use of remdesivir (GS-5734) in a patient with a double lung transplant and afflicted with COVID-19 is described.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses
TLDR
The antiviral activities of GS-5734 and the parent nucleoside analog across multiple virus families are reported, providing evidence to support new indications for this compound against human viruses of significant public health concern.
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
TLDR
In vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients are evaluated.
Metabolism and Pharmacokinetics of the Anti-Hepatitis C Virus Nucleotide Prodrug GS-6620
TLDR
Following oral administration of anti-hepatitis C virus nucleotide prodrug GS-6620, intact prodrug levels in blood plasma were the highest in dogs, followed by monkeys, and then were the lowest in hamsters, suggesting relatively poor oral absorption in humans was compensated for by relatively efficient hepatocyte activation.
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
TLDR
It is shown that GS-5734 inhibits murine hepatitis virus (MHV) with similar 50% effective concentration values (EC50) as SARS-CoV and Middle East respiratory syndrome coronavirus (MERS- coV) and that resistance can be overcome with increased, nontoxic concentrations of GS- 5734, further supporting the development of GS -5734 as a broad-spectrum therapeutic to protect against contemporary and emerging CoVs.
Remdesivir in The Treatment of COVID-19.
TLDR
The antiviral remdesivir is superior to placebo in the treatment of patients hospitalized with COVID-19 and a variety of therapeutic approaches are needed to continue to improve outcomes in patients.
Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis
TLDR
GS-441524 was shown to be a safe and effective treatment for FIP and the optimum dosage was found to be 4.0 mg/kg SC q24h for at least 12 weeks.
The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies
TLDR
In an experimental FIPV infection of cats, GS-441524 treatment caused a rapid reversal of disease signs and return to normality with as little as two weeks of treatment in 10/10 cats and with no apparent toxicity.
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
TLDR
These results show the first substantive post-exposure protection by a small-molecule antiviral compound against EBOV in nonhuman primates, and the broad-spectrum antiviral activity of GS-5734 in vitro against other pathogenic RNA viruses, including filoviruses, arenavirus, and coronavirus suggests the potential for wider medical use.
Remdesivir for the Treatment of Covid-19 — Final Report
TLDR
The data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses
TLDR
A robust diastereoselective synthesis provided sufficient quantities of 4b to enable preclinical efficacy in a non-human-primate EBOV challenge model and structure activity relationships established that the 1′-CN group and C-linked nucleobase were critical for optimal anti-EBOV potency and selectivity against host polymerases.
...
1
2
3
4
5
...